The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma.
M. Nishio
No relevant relationships to disclose
T. Yamanaka
No relevant relationships to disclose
K. Matsumoto
No relevant relationships to disclose
H. Kimura
No relevant relationships to disclose
K. Sakai
No relevant relationships to disclose
A. Sakai
No relevant relationships to disclose
T. Sone
No relevant relationships to disclose
A. Horiike
No relevant relationships to disclose
F. Koizumi
No relevant relationships to disclose
K. Kasahara
No relevant relationships to disclose
T. Ohira
No relevant relationships to disclose
N. Ikeda
No relevant relationships to disclose
N. Saijo
No relevant relationships to disclose
T. Arao
No relevant relationships to disclose
K. Nishio
No relevant relationships to disclose